Phospho-TrkB (Tyr817)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 3732R
英文名称Phospho-TrkB (Tyr817)
中文名称磷酸化酪氨酸激酶B(Tyr817)抗体
别 名TrkB (phospho Y817); p-TrkB (phospho Y817); TrkB (Phospho-Tyr817); TrkB (Phospho Tyr817); TrkB (Phospho-Y817); p-TrkB(Tyr817); AI848316; BDNF tropomyosine receptor kinase B; BDNF/NT 3 growth factors receptor; BDNF/NT-3 growth factors receptor; Brain derived neurotrophic factor receptor; C030027L06Rik; EC 2.7.10.1; GP145 TrkB; GP145-TrkB; GP145-TrkB/GP95-TrkB; GP95 TrkB; Neurotrophic tyrosine kinase receptor type 2; Neurotrophin receptor tyrosine kinase type 2; NTRK 2; Ntrk2; NTRK2_HUMAN; Obesity, hyperphagia, and developmental delay, included; RATTRKB1; Tkrb; Trk B; Trk-B; TRKB; TrkB tyrosine kinase; TRKB1; Tropomyosin related kinase B; tyrosine kinase receptor B; Tyrosine receptor kinase B.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 细胞生物 **学 神经生物学 信号转导 转录调节因子 激酶和磷酸酶
抗体来源Rabbit
克隆类型Polyclonal
Phospho-TrkB (Tyr817)抗体交叉反应 Human, Mouse, Rat,
产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量90kDa
细胞定位细胞浆 细胞膜
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human TrkB around the phosphorylation site of Tyr817:PV(p-Y)LD
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-TrkB (Tyr817)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
This gene encodes a member of the neurotrophic tyrosine receptor kinase (NTRK) family. This kinase is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Signalling through this kinase leads to cell differentiation. Mutations in this gene have been associated with obesity and mood disorders. Alternate transcriptional splice variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008].
Function:
Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades. Through SHC1, FRS2, SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for instance neuronal differentiation including neurite outgrowth. Through the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade that mainly regulates growth and survival. Through PLCG1 and the downstream protein kinase C-regulated pathways controls synaptic plasticity. Thereby, plays a role in learning and memory by regulating both short term synaptic function and long-term potentiation. PLCG1 also leads to NF-Kappa-B activation and the transcription of genes involved in cell survival. Hence, it is able to suppress anoikis, the apoptosis resulting from loss of cell-matrix interactions. May also play a role in neutrophin-dependent calcium signaling in glial cells and mediate communication between neurons and glia.
Subunit:
Exists in a dynamic equilibrium between monomeric (low affinity) and dimeric (high affinity) structures. Interacts (phosphorylated upon activation by BDNF) with SHC1; mediates SHC1 phosphorylation and activation. Interacts (phosphorylated upon activation by BDNF) with PLCG1 and/or PLCG2; mediates PLCG1 phosphorylation and activation. Interacts with SH2B1 and SH2B2. Interacts with NGFR; may regulate the ligand specificity of the receptor. Interacts (phosphorylated upon ligand-binding) with SH2D1A; regulates NTRK2. Interacts with SQSTM1 and KIDINS220. Interacts (phosphorylated upon ligand-binding) with FRS2; activates the MAPK signaling pathway.
Subcellular Location:
Cell membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Note=Internalized to endosomes upon ligand-binding.
Tissue Specificity:
Isoform TrkB is expressed in the central and peripheral nervous system. In the central nervous system (CNS), expression is observed in the cerebral cortex, hippocampus, thalamus, choroid plexus, granular layer of the cerebellum, brain stem, and spinal cord. In the peripheral nervous system, it is expressed in many cranial ganglia, the ophtalmic nerve, the vestibular system, multiple facial structures, the submaxillary glands, and dorsal root ganglia. Isoform TrkB-T1 is mainly expressed in the brain but also detected in other tissues including pancreas, kidney and heart. Isoform TrkB-T-Shc is predominantly expressed in the brain.
Post-translational modifications:
Phosphorylated. Undergoes ligand-mediated autophosphorylation that is required for interaction with SHC1 and PLCG1 and other downstream effectors. Isoform TrkB-T-Shc is not phosphorylated.
Ubiquitinated. Undergoes polyubiquitination upon activation; regulated by NGFR. Ubiquitination regulates the internalization of the receptor.
DISEASE:
Defects in NTRK2 are the cause of obesity hyperphagia and developmental delay (OHPDD) [MIM:613886]. OHPDD is a disorder characterized by early-onset obesity, hyperphagia, and severe developmental delay in motor function, speech, and language.
Similarity:
Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.
Contains 2 Ig-like C2-type (immunoglobulin-like) domains.
Contains 2 LRR (leucine-rich) repeats.
Contains 1 LRRCT domain.
Contains 1 LRRNT domain.
Contains 1 protein kinase domain.
SWISS:
Q16620
Gene ID:
4915
Phospho-TrkB (Tyr817)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-TrkB (Tyr817)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 合格 5HT1F Receptor 5-羟色胺受体1F抗体
合格 5HT2A Receptor 5-羟色胺受体2A抗体
合格 合格 5HT2B Receptor 5-羟色胺受体2B抗体
合格 5HT7 Receptor 5-羟色胺受体7抗体
合格 合格 ROCK2 Rho相关蛋白激酶2抗体
合格 合格 合格 GABRA2 G氨基丁酸A型受体α2/GABAA Rα2抗体
合格 GABRB2 G氨基丁酸受体β2/GABAA Rβ2抗体
合格 TLX2 T**细胞白血病同源蛋白2抗体
合格 合格 合格 GLI1 脑胶质瘤相关蛋白抗体（锌指蛋白5）
合格 P2Y10 G蛋白偶联嘌呤受体p2y10抗体
合格 P2Y8 G蛋白偶联嘌呤受体p2y8抗体
合格 合格 P2Y9 G蛋白偶联嘌呤受体p2y9抗体
合格 GLUT3 葡萄糖转运蛋白3抗体
合格 GABRG3 G氨基丁酸受体γ3/GABAA Rγ3抗体
合格 GABRR1 G氨基丁酸A型受体rho1/GABAA Rρ1抗体
合格 KCTD8 钾离子通道多聚体结构域蛋白8抗体
合格 ADAMTS1 整合素样金属蛋白酶与凝血酶1型抗体
合格 CNGB3 环核苷酸门控阳离子通道蛋白β3/CNG-β3抗体
合格 合格 GRINA 谷氨酸受体相关蛋白1抗体
合格 NR3B 谷氨酸受体3B抗体
合格 NMDAR3A + 3B 谷氨酸受体3A+3B抗体
合格 P2RX7 嘌呤受体P2X7抗体
合格 合格 P2RX1 三磷酸腺苷受体受体P2X1抗体
合格 合格 P2X5b 三磷酸腺苷受体P2X5b抗体
合格 合格 P2RX6 三磷酸腺苷受体P2X6抗体